This study evaluated one-year atrial fibrillation (AFib) rates by age among patients with chronic lymphocytic leukemia (CLL) in the US Symphony database and assessed AFib risk across 2-year age groups among patients who received first-line covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy.
This was a retrospective analysis of the US Symphony database. Adult CLL patients aged 55 to 79 years were identified; the exact age of patients aged ≥80 years could not be determined due to privacy protections. One-year AFib rates were assessed by single year of age among the overall CLL population. A further exploratory analysis was conducted among patients who received first-line cBTKi, summarizing 1-year AFib rates across 2-year age groups. A second descriptive analysis excluded patients with pre-existing AFib at baseline, defined as an AFib diagnosis occurring in the 1 year on or before the index date. No adjusted head-to-head comparisons between cBTKi treatments were performed.
A total of 213,473 CLL patients aged 55-79 years were identified. The mean Charlson Comorbidity Index (CCI) score was 3.1. Key comorbidities included hypertensive disease (43.2%), heart disease (21.1%), diabetes mellitus (19.3%), kidney disease (13.9%), other cancers (13.5%), COPD (8.0%), cerebrovascular disease (6.0%), liver disease (4.6%), and peripheral vascular disease (3.9%).
The 1-year rate of AFib increased linearly with age, from 3.5% at age 55 to 13.6% at age 70 and 24.7% at age 79. In the sensitivity analysis excluding patients with pre-existing AFib, the 1-year rate of new-onset AFib increased progressively from 1.9% at age 59 to 5.5% at age 70 and 8.6% at age 79.
Among patients who initiated first-line cBTKi therapy, 14,243 received ibrutinib, 5,105 received acalabrutinib, and 1,777 received zanubrutinib. Mean CCI scores were 3.3 with zanubrutinib, 3.3 with acalabrutinib, and 2.8 with ibrutinib; rates of heart disease, hypertensive disease, diabetes, and kidney disease were numerically higher in the zanubrutinib and acalabrutinib cohorts. Among patients who received 1L ibrutinib, AFib rates were 5.1% at ages 55-56, 16.6% at ages 69-70, and 22.8% at age 79. Corresponding rates for 1L acalabrutinib were 4.4%, 12.3%, and 18.6%, respectively, and for 1L zanubrutinib were 0%, 9.5%, and 16.0%, respectively. Overall, AFib rates by 2-year age group with 1L zanubrutinib were consistently lower than those observed with 1L ibrutinib and 1L acalabrutinib across all age strata. Among patients without baseline AFib (ibrutinib: n=13,050; acalabrutinib: n=4,535; zanubrutinib: n=1,579), new-onset AFib rates followed similar patterns but were uniformly lower, ranging from 3.8%-15.5%, 0.8%-10.3%, and 0%-7.0%, respectively.